Role of molecular markers and gene profiling in head and neck cancers

Current Opinion in Oncology

Volumn 21, Issue 3, 2009, Pages 206-211

  Gold, Kathryn A ^a   Kim, Edward S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Box 432 ^*  (United States)

Author keywords

Biomarkers; Epidermal growth factor receptor; HPV; P53; Squamous cell carcinoma of the head and neck

Indexed keywords

ALPHA CATENIN; AMPHIREGULIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR MARKER; MYC PROTEIN; NIBRIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 1 RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; TUMOR MARKER;

ALCOHOL CONSUMPTION; CANCER DIAGNOSIS; CARCINOGENESIS; CLINICAL PRACTICE; DISEASE CLASSIFICATION; GENOME; HEAD AND NECK CANCER; HUMAN; NONHUMAN; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; WART VIRUS; GENE EXPRESSION PROFILING; GENETICS; HEAD AND NECK TUMOR; ISOLATION AND PURIFICATION; METABOLISM; PAPILLOMA VIRUS; PATHOGENICITY; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650360215     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328329ac00     Document Type: Review

References (65)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4:156-171.
3. Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Br Med J 2002; 325:822-827.
4. Almadori G, Bussu F, Cadoni G, et al. Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review. Eur J Cancer 2004; 40:2383-2388.
5. Nees M, Homann N, Discher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993; 53:4189-4196.
6. Waridel F, Estreicher A, Bron L, et al. Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract. Oncogene 1997; 14:163-169.
7. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001; 7:3127-3134.
8. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359:1143-1154. An excellent review of recent advances in the diagnosis and treatment of HNSCC.
9. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-1174.
10. Sheikh-Ali MAL, Gunduz M, Nagatsuka H, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008; 99:1589-1594. This study demonstrates that, although EGFR is frequently overexpressed in HNSCC, mutations are rare.
11. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11:1873-1878.
12. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26:3128-3137.
13. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832.
14. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Group study. J Clin Oncol 2005; 23:8646-8654.
15. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356.
16. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127. This article reports the results of a recent phase III trial that showed a benefit in adding cetuximab to platinum-based chemotherapy in recurrent/metastatic head and neck cancer.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
18. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, and oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
19. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25:2178-2183.
20. Agulnik M, Santos Gd C, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25:2184-2190.
21. Yonesaka K, Zejnullahu K, Lindeman N, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancer. Clin Cancer Res 2008; 14:6963-6973. This study shows that amphiregulin is a potential marker for sensitivity to anti-EGFR treatment.
22. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
23. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-475.
24. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-720.
25. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956. This elegant case-control study implicates HPV as a causative agent in oropharyngeal carcinoma.
26. Braakhuis BJM, Snijders PJ, Keune W-JH, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96:998-1006.
27. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136.
28. Psyrri A, DiMaio D. Human papillomavirus in cervical and head and neck cancer. Nat Clin Prac Oncol 2008; 5:24-31.
29. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharnyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630-5636.
30. Worden F, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26:3138-3146. This study demonstrates improved survival in patients with HPV-associated oropharyngeal carcinoma.
31. Group TFIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-1927.
32. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
33. Foulkes WD. p53: master and commander. N Engl J Med 2007; 357:2539-2541.
34. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23:276-292.
35. Boyle JO, Hakim J, Koch WM, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53:4477-4480.
36. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332:712-717.
37. Erber R, Conradt C, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16:1671-1679.
38. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357:2552-2561. This study relates the type of p53 mutation to impact on survival and notes that only disruptive mutations affect prognosis.
39. Kumar B, Cordell KG, d'Silva NJ, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008; 134:363-369.
40. Westra WH, Taube JM, Poeta ML, et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14:366-369. This analysis demonstrates that p53 mutations are rarely found in HPV-positive tumors, further evidence that HPV-positive and HPV-negative tumors have different genetic changes.
41. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049.
42. Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999; 5:775-782.
43. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107:873-877.
44. Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13:4291-4299. This study demonstrates in HNSCC cell lines that inhibition of IGF-1R with either siRNA or antibodies can slow growth. It highlights IGF-1R as a therapeutic target in HNSCC.
45. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Brit J Cancer 2008; 99:167-172. This study offers evidence that increased expression of a DNA-damage repair enzyme may be a mechanism of cisplatin resistance in HNSCC.
46. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatinbased induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13:3855-3859.
47. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60:23-32.
48. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112:638-644.
49. Marsit CJ, Black CC, Posner MR, et al. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14:2371-2377. This study demonstrates that a genetic variant in cyclin D1 can increase a patient's risk of developing squamous cell carcinoma.
50. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16 (MTS1/CKD4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002; 112:472-481.
51. Zavadil J, Haley J, Kalluri R, et al. Epithelial-mesenchymal transition. Cancer Res 2008; 68:9574-9577.
52. Foschini MP, Cocchi R, Morandi L, et al. E-cadherin loss and Delta Np73L expression in oral squamous cell carcinomas showing aggressive behavior. Head Neck 2008; 30:1475-1482. This study examines the epithelial-mesenchymal transition, and demonstrates that head and neck tumors that have undergone this transition have more aggressive behavior.
53. Kurtz KA, Hoffman HT, Zimmerman MB, et al. Decreased E-cadherin but not beta-catenin expression is associated with vascular invasion and decreased survival in head and neck squamous carcinomas. Otolaryngol Head Neck Surg 2006; 134:142-146.
54. Yang MH, Chang SY, Chiou SH, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007; 26:1459-1467.
55. Fuchs BC, Fujii T, Dorfman JD, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68:2391-2399.
56. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of nonsmall-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65:9455-9462.
57. Byers LA, Kies MS, William WN, et al. Profiling of cytokines and angiogenic factors in head and neck cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. ASCO Meeting Abstracts 2008; 26:6005. This study shows that serum biomarkers as well as tissue biomarkers can be used for risk stratification.
58. Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, et al. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with nonsmall cell lung cancer and head and neck carcinoma. Br J Cancer 2007; 96:1569-1578.
59. Moustafa A-EA, Alaoui-Jamali MA, Batist G, et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002; 21:2634-2640.
60. Roepman P, Wessels LFA, Kettelarij N, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genetics 2005; 37:182-186.
61. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007; 25:4350-4357.
62. Ganly I, Talbot S, Carlson D, et al. Identification of angiogenesis/metastases genes predicting chemotherapy response in patients with laryngopharyngeal carcinoma. J Clin Oncol 2007; 25:1369-1376.
63. Akervall J. Genomic screening of head and neck cancer and its implications for therapy planning. Eur Arch Otorhinolaryngol 2006; 263:297-304.
64. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
65. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.